

31. (amended) An immunogenic [A vaccine] composition for immunizing a mammal comprising [a peptide according to any one of claims 1, 9, 15 or 22] an immunogenically-effective amount of gp100 (SEQ ID NO:27) or an immunogenic peptide having contiguous amino acids within the gp100 sequence in a pharmacologically acceptable carrier.

REMARKS

Applicants respectfully request favorable consideration of the present application and claims. Early and favorable action by the Examiner is earnestly solicited.

No additional fee is believed to be necessary.

The Commissioner is hereby authorized to charge any additional fees which may be required for this amendment, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2026-4124US3.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition and for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 13-4500, Order No. 2026-4124US3. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: May 5, 1998

By: 

Dorothy R. Auth  
Registration No. 36,434

MORGAN & FINNEGAN  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Telecopier

EE065891187US